Roche’s Genentech has reported new five-year data from the Phase III Portal trial, confirming the safety, durability, and efficacy of Susvimo (ranibizumab injection) for treating wet age-related macular degeneration (AMD).
This long-term extension of the Phase III Archway trial demonstrated that approximately 95% of patients receiving the injection required no additional treatment before each six-month refill.
The findings, presented at the American Society of Retina Specialists (ASRS) 2025 Annual Meeting in California, US, indicated that Susvimo maintained consistent disease control and retinal drying in patients who had previously achieved near-peak vision levels.
The Portal study involved 352 participants and individuals who had initially been administered Susvimo in the Archway trial and were given subsequent Susvimo refills on a biannual basis.
Those who had initially received monthly intravitreal (IVT) injections of ranibizumab in the Archway trial were transitioned to Susvimo, with subsequent refills scheduled every six months.
In the Susvimo cohort, subjects maintained an average best-corrected visual acuity (BCVA) of 67.6 letters after five years, from a baseline of 74.4 letters.
The IVT-Susvimo cohort showed a BCVA of 68.6 letters at a five-year period, from a 76.3 baseline.
Average central subfield thickness (CST) stayed stable across both cohorts while 50% of subjects retained better than 20/40 vision over five years.
Susvimo operates through the Port Delivery Platform and offers a constant delivery of ranibizumab.
Genentech global product development head and chief medical officer Levi Garraway said: “These long-term results reinforce Susvimo’s ability to maintain vision and retinal drying over a long period of time for people with wet AMD, the leading cause of vision loss in people over age 60.”
The multi-centre, randomised, open-label Archway trial compared the injection refills every six months to 0.5mg monthly IVT ranibizumab in 415 wet AMD patients.
Following the conclusion of the Archway trial at week 96, subjects were eligible to participate in the Portal extension trial.
